anonymous
Guest
anonymous
Guest
Truth on $170. Big risk should pay a big reward.
Agree that $170 isn’t stupidly high considering this is an orphan drug that will be hard to sell, maybe 3-4 patients per rep annually. Price tag $2-$3M per this weeks news from JP Morgan Healthcare Summit.
FUCK YOU!!Do your homework. Valrox will not be hard to sell and will be used much more than “3-4 patients per rep annually.” Ever talk to a hematologist?
Jackass.
FUCK YOU!!
Heme’s are one thing but insurance is another w a $2-3Million price tag not to mention 6 months of labs that some patients may decide is too much work.Do your homework. Valrox will not be hard to sell and will be used much more than “3-4 patients per rep annually.” Ever talk to a hematologist?
Jackass.
Ya know... this company literally preaches “culture” of rising above & “keeping the patients at the center of everything” & how important it is to stay humble. THIS is apparently what they hire. Pfizer will eat your lunch when their product is approved. Until then Hemlibra is still an amazing drug & as the mom of a teen boy w type A we’ll wait until then.FUCK YOU!!
It's OK. Average for these size territories. .Serious question, is $800 plus mileage car allowance competitive? I’ve had fleet cars for 15 years.
Ya know... this company literally preaches “culture” of rising above & “keeping the patients at the center of everything” & how important it is to stay humble. THIS is apparently what they hire. Pfizer will eat your lunch when their product is approved. Until then Hemlibra is still an amazing drug & as the mom of a teen boy w type A we’ll wait until then.
ITS SHIT!!!It's OK. Average for these size territories. .
the hemophilia community doesn’t need a gene therapy...... HeMlibra is providing patients with a new leash in life....... why would anyone risk taking this product with so much variability in the data........ until they can answer the variability you should wait
Do your homework. Valrox will not be hard to sell and will be used much more than “3-4 patients per rep annually.” Ever talk to a hematologist?
Jackass.
This is about exactly right, I negotiated for $175K and a sign on bonus, but everything else is accurate. It’s a $275-$300k a year job. This is rare Disease and extremely high paying for pharma (Pfizer won’t sniff that), and very high paying for biotech. In this day and age, maybe some Oncology or equipment jobs get to this, hardly anything else.Was quoted $160-$170k bass range, $60k bonus, $800 per month car allowance, $50k in RSUs. Hearing different stories as to why they haven’t secured sales team. Was told by RX Sales recruiter that Phase 1 was already hired Fall 2019 and Phase 2 be hired by Mar 15. Anyone hired Phase 1? ???
I work for Alnylam in this exact role. Almost every number you reference “we” make is high. I wish you were more accurate. Cat is right, that’s about it. You might be referencing 10% of us here.Look @ Alnylam. Rare Disease Hereditary Transtheritn Amyloidosis. Reps making 195k in base, 60-100k in bonus. Huge RSU stock upon hire and annually rewarded and company car is a Volvo XC90. Company’s pipeline is exploding too. Not a one hit wonder! Check them out they are hiring in an expansion right now.
I work for Alnylam in this exact role. Almost every number you reference “we” make is high. I wish you were more accurate. Cat is right, that’s about it. You might be referencing 10% of us here.
What are you talking about. I’m in the interview process now and have spoken to 4 Alnylam Reps. The numbers the above poster referenced are spot on. Know your suit bevies you spew out nonsense punk. Now enjoy BioMarin. I had a phone screen with the hiring manager and he was extremely arrogant. Have fun with that shirshow.I work for Alnylam in this exact role. Almost every number you reference “we” make is high. I wish you were more accurate. Cat is right, that’s about it. You might be referencing 10% of us here.